Loading...
•
Mar 31, 2023
Inovio Q1 2023 Earnings Report
Inovio reported financial results and operational highlights.
Key Takeaways
Inovio reported a net loss of $40.6 million, or $0.16 per share, for the quarter ended March 31, 2023. The company ended the quarter with $223.8 million in cash, cash equivalents and short-term investments and expects its cash runway to extend into the first quarter of 2025.
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients.
Announced positive data from Phase 1b trial with INO-4201 as an Ebola booster for ERVEBO®.
Announced topline results for REVEAL2, the second Phase 3 trial for VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions.
Ended the first quarter 2023 with $223.8 million in cash, cash equivalents and short-term investments.
Forward Guidance
INOVIO continues to expect its cash runway to extend into the first quarter of 2025. This projection includes a cash burn estimate of approximately $33 million for the second quarter 2023 and its ongoing expectation that cash burn will decrease incrementally from there into the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...